Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton, Dickinson and Co.

The U.S. Securities and Exchange Commission said on Monday that it had settled charges with Becton Dickinson and Co. over allegations it misled investors about risks associated with its Alaris infusion pump.

Becton Dickinson settles charges over infusion pump risks, SEC says

Washington, D.C.--(Newsfile Corp. - December 16, 2024) - The Securities and Exchange Commission today announced settled charges against Becton, Dickinson and Company, a New Jersey-based medical device manufacturer known as BD, for repeatedly misleading investors about risks associated with its continued sales of its Alaris infusion pump and for overstating its income by failing to record the costs of fixing multiple software flaws with the pump.

Becton Dickinson to Pay $175 Million for Misleading Investors About Alaris Infusion Pump

Becton, Dickinson and Company is projected to achieve 8.8%-9.3% revenue growth in FY25, driven by new product launches and the APM business. The acquisition of Edwards Lifesciences' Critical Care product group is expected to significantly boost BD's Advanced Patient Monitoring segment. BD plans to reduce debt leverage to 2.5x and repurchase $1 billion in shares, enhancing financial stability and shareholder value.

Becton, Dickinson and Company Q4: Shifting To High-Growth Areas

Becton Dickinson surpassed analysts' expectations for fourth-quarter results on Thursday, helped by strong demand for its drug-delivery devices.

Becton Dickinson beats quarterly estimates on strength in drug-delivery devices

This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. I expect 13 companies to announce their annual increases in the first half of November, including double-digit increases from Automatic Data Processing, Roper Technologies, and Snap-on. Investors saw good 10%+ increases from insurer Brown & Brown, payment processor Visa, and specialty chemical company RPM in October.

Becton, Dickinson And HP Among 13 Companies To Announce Annual Dividend Increases In First Half Of November

I reiterate a 'Buy' rating for BDX with a fair value of $265 per share, driven by growth in GLP-1 drug delivery and the acquisition of Edwards Lifesciences' Critical Care. BDX's strong market position in prefilled syringes and self-administered injection systems positions it to benefit significantly from the fast-growing GLP-1 market, potentially adding $1 billion in revenue by 2030. The acquisition of Edwards Lifesciences' Critical Care product group for $4.2 billion is expected to accelerate BDX's revenue growth and expand margins, enhancing its smart connected care solutions.

Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery

Becton, Dickinson is overwhelmingly considered undervalued by Wall Street analysts, with an average price target of ~$280 and highs of $312-$330. This is supported by my extensive DCF and comps models. BDX benefits from innovative products, strategic partnerships, and ongoing trends. The company boasts high margins and a reliable, growing dividend. However, the price is already pretty close to its all-time high and most price targets, so significant further appreciation is unlikely, making BDX a very moderate "Buy".

Becton, Dickinson And Company: Somewhat Undervalued, A Very Moderate Buy

Becton Dickinson reported a better-than-expected third-quarter profit on Thursday, helped by strong demand for its drug-delivery devices.

Becton Dickinson tops profit estimates on demand for drug-delivery devices

Medical-supply company looks to fill gaps as former supplier restarts production of vials.

Becton Dickinson's stock bounces as FDA addresses supply issue with blood-culture vials

The U.S. Food and Drug Administration issued an alert on Wednesday to laboratories and healthcare providers of a shortage of Becton Dickinson' blood test tubes used in diagnosing bacterial and fungal infections.

US FDA flags shortage of Becton Dickinson's blood test tubes

Edwards Lifesciences

The buyer intends to fund deal with a combination of $1 billion in cash and $3.2 billion of new debt in a transaction that is one of its largest of many.

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash

Edwards Lifesciences on Monday said it has agreed to sell its Critical Care products unit to Becton Dickinson in an all-cash transaction valued at $4.2 billion.

Edwards Lifesciences to sell critical care products unit to Becton Dickinson for $4.2 bln

Shares of Edwards Lifesciences Corp. EW, -1.14% rallied 3% in premarket trading Monday, after the company announced an agreement to sell its critical care product group to Becton Dickinson & Co. BDX, +2.29% in a cash deal valued at $4.2 billion. Edwards said it plans to use the proceeds from the sale to fund investments for growth, such as in technologies for technologies for aortic, mitral, tricuspid and pulmonic patients, and in therapeutic areas for interventional heart failure.

Edwards Lifesciences to sell its critical care product group for $4.2 billion to Becton Dickinson

Polaris

Value investing may be out of favor due to the success of tech darlings like Nvidia and Amazon. However, value investing can still be done safely and responsibly, and generate exceptional returns, including 15% to 25% annual returns over several years. Dividend aristocrats like Becton, Dickinson and Polaris are trading at 52-week lows and present potentially attractive buying opportunities.

Becton, Dickinson And Polaris: The Market Is Dead Wrong About These Dividend Aristocrat Bargains

Becton Dickinson raised its annual profit forecast and beat second-quarter profit estimates on Thursday, as the group banks on strong demand for its surgical equipment and syringes.

Becton Dickinson lifts profit view on strong surgical equipment demand

Becton Dickinson said on Thursday that it will increase domestic production of medical syringes.

Becton Dickinson to increase domestic production of syringes

Becton, Dickinson and Company (BD) experienced weak growth in China, with a decline of 5.3% year-over-year. BD's major challenges, including the Alaris pump and Covid comparisons, are starting to normalize. The stock price is undervalued, leading to an upgrade in rating from 'Hold' to 'Buy' with a fair value of $250 per share.

Becton, Dickinson And Company: Growth Starts To Normalize (Rating Upgrade)

Becton Dickinson beat first-quarter profit estimates and raised its full-year earnings forecast on Thursday as it benefits from strong demand for its surgical equipment.

Becton Dickinson lifts 2024 profit forecast on surgical devices strength

Becton, Dickinson and Company has underperformed the market and healthcare sector in recent years. The company's balance sheet has improved significantly which I believe will allow for increased returns of capital to shareholders going forward. BDX's recent guidance for FY 2024 has lowered earnings expectations, but the company has a history of beating consensus estimates.

Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play

In an interview with CNBC's Jim Cramer, Becton Dickinson CEO Tom Polen described how the medical device manufacturer's new technology can save hospitals money.

Becton Dickinson CEO describes how new technology helps hospitals fight inflated operating costs

Becton Dickinson said on Thursday the U.S. Food and Drug Administration (FDA) had cleared its less invasive blood collection device.

US FDA clears Becton Dickinson's blood collection device

Acutus Medical

Eagle Pharmaceuticals

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Could Blast Off This Quarter - Acutus Medical (NASDAQ:AFIB), Becton Dickinson (NYSE:BDX)

Becton, Dickinson, and Company is a healthcare company with strong fundamentals and a history of dividend growth. The company has shown robust execution of its 2025 strategy, positioning it for sustained growth and innovation in the medical technology space. However, there are risks to the investment, including slower EPS growth, competition, and a lack of margin of safety in the current valuation.

Following The Q4 Results, Becton, Dickinson and Company Is Still A Hold

Disney

Tesla

U.S. equities fell midday ahead of comments from Fed Chair Jerome Powell that could offer clues about the future of monetary policy. The Dow, S&P 500, and Nasdaq were all lower.

Midday Movers: Disney Rises, Tesla and Becton Dickinson Fall

AbbVie

Automatic Data Processing

American Electric Power Company

A. O. Smith

Amphenol

Black Hills

Brown & Brown

Evergy Inc

Gorman-Rupp

Lincoln Electric Hlds

Lockheed Martin

Visa and Exxon Mobil announced dividend increases in October, with Visa increasing its dividend by 15.6% and Exxon Mobil increasing its dividend by 4.4%. Several companies, including AbbVie, American Electric Power, and McDonalds, met or exceeded dividend increase predictions in October. Dividend growth slowed for companies like Amphenol, Black Hills, and Tompkins Financial due to various factors such as the current economic slowdown and flat or lower earnings.

News for Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A Stock (BDXA)